More than three years after Gilead Sciences’ targeted hepatitis D virus (HDV) candidate bulevirtide was turned down by the U.S.... Read more
Category: Uncategorized
Lantheus evaluates $7 billion buyout offer from Curium amid radiopharmaceutical sector boom
The global life sciences ecosystem is registering intensive consolidation momentum as Massachusetts-based Lantheus Holdings considers a multi-billion-dollar takeover proposal from... Read more
Vietnamese maternal and child market shifts heavily toward origin transparency and authorized distribution
The maternal and child product sector in Vietnam is experiencing a profound paradigm shift in consumer behavior. Beyond traditional price... Read more
Vietnam’s Ministry of Health issues new Circular governing free drug programs, strictly prohibiting advertising exploitation
The Permanent Vice Minister of Health has officially signed into effect a comprehensive Circular outlining strict regulatory requirements for implementing... Read more
WHO honors Vietnam’s tobacco control milestones, urges full legalization of e-cigarette bans
The World Health Organization (WHO) has highly commended Vietnam’s strategic structural interventions in regulating novel tobacco products during a high-level... Read more
Vietnam Military-Civil Medicine Association partners with Sunwah Group to drive high-tech herbal medicine exports
On May 27, the Vietnam Military-Civil Medicine Association held an official working session at the Ministry of Health with China-based... Read more
Tasco Pharma deploys over 200 billion VND to anchor major stake in Pharmedic amid eye drop product recall
The equity ownership architecture of Pharmedic Pharmaceutical Medicinal Joint Stock Company (Ticker: PMC) has undergone a major transition, with Tasco... Read more
Sakar Healthcare partners with Zydus Lifesciences for oncology supply across GCC markets
Specialty pharmaceutical manufacturer Sakar Healthcare has finalized a definitive supply agreement with Zydus Lifesciences to distribute its oncology product portfolio... Read more
Eli Lilly advances to Phase 2 trials for Verve’s gene-editing therapy following robust cholesterol-lowering data
Biopharmaceutical giant Eli Lilly is finalizing clinical preparations to launch a Phase 2 study for an investigational lipid-lowering gene-editing asset... Read more








